Sarepta Therapeutics shares traded lower in premarket trade on Tuesday, as the drugmaker relented to a Food and Drug ...

Sarepta Therapeutics’ stock has dropped precipitously as questions swirl around the safety of its gene therapies. Meanwhile, the Duchenne patient community fears losing access to Elevidys while the ...

Opendoor Technologies shares are up nearly 12% as traders continue to buy the meme stock after [Monday's extreme volatility]( ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

Sarepta faces FDA scrutiny over Elevidys as analysts downgrade stock and warn of long-term debt risks amid market uncertainty ...

Sarepta Therapeutics has rejected a call by the Food and Drug Administration to stop shipments of its muscular dystrophy drug.

Implied Volatility Surging for Sarepta (SRPT) Stock Options. Zacks Equity Research . Fri, May 24, 2024, 11:57 AM 2 min read. In This Article: SRPT .